All right, so Welcome everybody's thanks for being here My name is Alex Stelbach. I work in The open telecom cloud team at two systems as an architect. Oh Good afternoon. My name is Yue Fengpan. I'm senior cloud solutions architect at Huawei Okay, today we're gonna talk about Keystone and and and some L and how we put that all together and adapted and changed it to fulfill some requirements that Are not there a native keystone for some use cases that we have in the open telecom cloud first of all That talk should have been given by my colleague Stefan Eisenblatter who was unfortunately not able to join us here So I'm just standing in for him be able with me if I'm not 100% fit in everything, but I will try to to give as much insight as possible So first of all, we want to have a quick look at what some L is what keystone is That's just a very short recap everyone everyone should know then I'm going to talk about the use cases and challenges we see in the open telecom cloud and after that I will hand over to you Feng for the Implementation part. So first of all keystone and some Summer is just a security assertion markup language currently in version two to zero It's a standard to exchange authorization and authentication information between different security domains and The main point it provides is just it allows that a service provider can rely on authorities or on identities that are issued by a different Let's say authority which is which is called the identity provider So it's commonly used for web-based single sign-on scenarios and it's pretty easy to to administer So what happens with summer is the the user just tries to log in at the service provider, which is Keystone in the open telecom cloud in in our example The service provider then just gives back a redirection to the to the real identity provider So that the request is so to say forward the dare The external identity providers then doing the validation and locks the user on and returns an assertion tag That assertion tag is then again passed to the to the service provider again Which is keystone in our in our example and keystone then just grants you access Regarding your your rights that that you have in the in the environment so native keystone is well able to to Support some as a protocol But you can only configure a single identity provider per domain So it's not possible to To mix them up to use different ones and it needs to be configured by an administrator Which is sometimes not what you want to have in multi-tenant use cases and there's no API for all that federated token management configuring the identity provider as it has to be configured by the by the admin So we need an extension to support the requirements that we have which More than one identity provider and the ability to configure them on a on a tenant level That brings me right to the use cases that we have in an open telecom cloud basically we have to the first one is Rather easy It's just that we have Several customers which are all bound in there in their own keystone domain and every customer needs his own identity provider Which is pretty common for business customers. They want to integrate their cloud offering somewhere in their existing identity management That is something that could be configured with native keystone on an on the on the administrator level But for every new customer as a as a public cloud provider You would have to do that configuration manually, which is which is probably not what you want to do when you're trying to operate at scale and The second use case is even more complex It's where you have a customer with his own domain and inside of that domain. He uses different identity providers This is Simply not possible with with native keystone, so that's why we why we needed to do some extensions to keystone and to the API So once again that the challenges we see is first of all We do not want to have the administrator which is our operations team To do keystone configurations for every new identity provider that needs to be added because we get a new customer But we wanted to be configured through an API if on on on a tenant level second is That if you have Several regions in in in your open stack, which you will probably have if you if you scale it up to a certain level Then you still have only one single keystone service that might become a bottleneck And that is something we worked around by by introduction of a caching proxy for for keystone And of course as I mentioned we needed the ability to support more than one identity provider per keystone domain And that was just done by by patching and extending keystone So that's all for the introduction part and for the implementation part. I just hand over to you think Here you go Okay Thanks, Alex Now I will introduce our identity and the management access management service on open telecom cloud Okay First of all I will introduce our Service between the federated the keystone. Okay, this is the native keystone We just use horizon a patch server and the ship list or melon for several federal Identity Federation, but what we have done on open telecom cloud is that We used front-end We called I am front-end and we also use the cache proxy instead of ship list and all melon and We have a call service called Used the native keystone and we have some patch to the keystones so that we can Support more than one I taps for each tenant. Okay Okay, this is architecture of our service There are three models the first is Front-end front-end is provides Management authentication and account management at UIs and There are three compounds one I am console deployed at is deployed at Deliberated as delimited zooms and also eyes at the trust zooms so that it will be secreted and Second is a cached proxy cached proxy Just for roots and locally accessories the keystone call service which means that We will deploy one cached proxy for each regions and so that it will be accelerate quick case a keystone call service and The third one is our course call service. It includes also includes the keystone and Also a deep keystone database and also our Keystone patch and We also have an extension database Choose to store as to keep the additional information for the identity provider Okay From now on I will talk about what we have done with keystone and Samo. Okay. This is our call service and The native keystone also Is a with application and database here we use my circle as a back end database and deployed in active stand-by mode So usually If if user at the identity provider the information will be stored in the tables such as identity provider protocol mapping and so on so So what do we have done is that we? write a keystone patch and also create new tables for the additional information that Identity provider more identity provider will need so We create new tables such as extension Identity provider and so on and do not list all of the tables so that Take taking the advantage of the keystone extension support open telecom cloud will support up to 10 Identity providers For each tenant Okay, then next This is a workflow of how to create what we have done to create a new identity provider for a tenant First you just an adept Give the name you can yeah give the name as your wish And the second reduced and brought protocol currently we spot Samo protocol So this is a default Samo protocol here and The third step is to create mapping. Yeah mapping rules is which describes The permissions the groups and the permissions of open telecom cloud according to the user attributes from the identity provider, so If if you if you Configure the identity provider through the console we provide a default mapping rules here You can see remote a wide cloud and the name ID and For local we have a Virtual user We called Federation user it's a virtual the default virtual user with no other access but logging and the logout so It is helpful if you We start to Federated with open telecom cloud so with the default Mapping rule it will be convenience and easy to To trust each other, okay And the fourth step and this is our extension import metadata file Okay, I met you the file is Interface file that In the format of Support Samo protocol which contains public key binding end point and algorithm so The identity provider and the service provider keeps their private keys for corruption and They put the public key in the metadata file for the each other to yes to check the signature and so on so Here when in this interface when You use the interface although you the portal we will check the Format of the metadata file so that if it is not if it is Invalid and they will be an error so for easy troubleshooting so that It will be helpful for the customers then Okay, a new identity provider for tenants is created so Here we provide a login link For the users who want to do not a Different way to log into the open telecom cloud here you can see different from the if you use horizon and maybe and You use a job list at the login page and job list and select the the other identity provider and import your username password and Authenticate but here we provide a login link so that It is a different way and This end point information with Identity provider name protocol type and service Service URL so that it if you want to Visit the for example for Elastic server or elastic volume or you can add here and for the customers for the users it will be easy to access the Resources Okay, oh Okay, this is a process of federation authentication first the user attempts attempts to Access So several protect resources and so here our service I am service as a service provider Then we were here. We will try to find out as you know We support more than one identity providers for each tenant. So It is very important that we will try to find out Which identity provider and the metadata file is fit for this Access So here We do something as the keystone patch. We do the things to try to find out the correct right identity provider so that and and we will find out the binding and the point and reflect to the Okay, of course the binding and the point is is point to the identity provider Okay, then Then okay, we'd like to use the identity provider so Identity provider will validate the same request so if there is a node trust have built before this This request and the identity provider may be an error So we should build the chest Before we have do this visit so if the if the identity provider Validate the same request and it is success it will present Logging login form to the user so the user can import the user name passwords and or something else to Ostecate Choose the identity provider so and then the identity provider will validate the credentials and If this cassettes and it generate generate is a similar response Okay, then the user post the Samo response to the service provider here comes to Open telecom cloud Service so here Here we have to do something with the same old response Firstly, we should find out the Firstly we validate the same assertion first We have what we have done is that We just validate to the same old assertion once if the same if the same Samo assertion comes twice or more than twice and three or four times we will reject it so it is It is more secure than the already and then the original demo Okay, and we also will validate If it is because every same old assertion with a Samo response with a timestamp. We also will check if it is expired so if it is So if it is expired, we will we will also reject the same assertion so if the check if the Same assertion is valid then Of course, we go to the We try to we will try to use to a public key and to verify the signature and then comes up to the mapping rules and the mapping rules we will try to Mapping the attributes from the identity provider to our local groups and users Okay, and then Unscoped unscoped token and the project list will return and all user can with use the unscoped token and and the project name and to get a Sculpt token and also and if we use a console Then We will return will return to the protect resource to the user here a session is created for the users and and with the permissions with the right permissions here so that the user can operate and Visit and our console for the open stack resources so here This is the overall workflow of our Federation of authentications here with what we have done For the hardening is that the identity provide identity to provide a Discovery and also the same assertion check checking Of course what we have done to choose the workflow Okay, next Yeah, I'm sure how we delete identity provider for a tenant so and compared compared to the before to the To the before steps it will be simple just delete a mapping and delete the Protocol and delete to the ID IDP and this force these three steps use the native keystone APIs and the third one and delete the metadata file and this we have Write extension APIs to for the keystones of course then Okay, I I Want identity provider will be deleted from from this for for this tenant Okay, okay, yeah, as you have seen we have some We have some extension we have some extension APIs to keystones here one one for One for import a metadata file of the Add of a tenant and the one for or coring the content of the metadata file import imported by an Identity provider and the one for getting metadata content of our service so that It will be Convenient and easy for the users to create identity provider. So Here this is all about our I am called service so next I will talk about our Cached proxy so our cash proxy is just for use for roots and Accelerates Keystone services so The Cached proxy will deploy One cached proxy for one region and of course it includes several applications and Use the load balance and a database and we call the t-cache So that we can with help of the t-cache so we can help cash The essential credentials here and at the region so that they cannot they do not need to go to the cost a keystone service to get the information But there are some considerations that we have to we have to do first is that Secure cached Credential so which means that if we catch catch the the data so we should make sure that The catch the data will be secure. So here we make sure that Each region has its own certificate different which is different from the other regions and We also make sure that The data cached the data cached is also Under it corrupt she of course so that it will be secure and then Limited limit scope so So as our Open telecom cloud has many regions and available zones so that We just catch or we just catch the local regions so means that if the region one and also a region one Catch the proxy in region one, so it's only catch the info for just a region one not know for the other regions and Also, no sensitive data will be kept in the proxies Okay, and third it expiration so Which means that each catch catch the data with a time stamp and If it reaches the expiration as the data will be deleted automatically and also We have effective and reliable mechanism to make sure that the data Between the cached proxy and the code and the core keystone service is consistent so We have we have a mechanism that We will detect the dirty data so that if this appears we will delete delete the dirty dates and And so on so This will be helpful Here next I'm sure it's a sample of how how our Cached proxy works of course when Try to visit visit a resource for example then the API goes through the API gateway and to the cached Cached proxy so if it is fine that the data as a credential maybe something has cached here and It will be returned without going to the keystone core service. So and it's a well more efficient and On the hot on the other hand in region two If the user I try to access. Yeah first time to access the resources then Also goes through goes through the API gateway and Okay, also go to the cached proxy, but the cache proxy and find that oh no not nothing cached so it will go directly to the core service to the course service or of course keystone and get the credentials or the information they need and Returned so meanwhile If the data is not is not sensitive and of course the data is this region and The data will will kept will kept in our cache cached proxy so that next time the same way it it will be Like the left that left picture so This is how the cached proxy works and then This is all about our cached proxy Next I will talk about our front end our console so currently we support two ways to config to add or delete or config Fed identity provider one is through console and The other way is through API's So if you want to use API's you should use enhanced client or proxy which called EZP But it is convenient we if we use Portals so on our Websites or on our console we can create delete edit query and identity provider and also Download upload the metadata file and Also, we can do Create delete edit query the mapping rules Okay, okay here We can see our Console so here we can if you click create an identity provider So a new identity provider will will generate so here With the with the help we take advantage of the our keystone Extensions here we can support 10 identity providers for each tenant In the future tenants Can apply for more quotas on demand so but perhaps they have to pay more Okay, and Here Of course our portal we can see the The end point we have mentioned so that Users can use the login link and just log into our open telecom cloud and then and we also have a Button that we can upload or download the metadata file cause and we also Can yeah create and or edit the mapping rules Of course and what we have done to the mapping rules is that We have a visible console and to help the users If you know the mapping rules that it will it is complicated it's very Complicated for the beginners so here We provide Visible consoles that helps the users to create To edit out to create the mapping rules. So here we can see okay. Okay. We have a job list to that I'm sorry Of course job list for the user group you have created and then The edge builds the edge builds the also a job list for for the ideal For the ideal specifications or the also usually also the or RG specifications and also we can Select the Conditions here and there's a visual then if we click okay create then it Will transfer into the JSON format so here It is Easy for the users to use our console to generate the mapping rules here the user so the remote user with edge builds about ideal person principle name and With a visual of CC CC then match to look our local Group CC test. So and with a display name of this This name. Okay Okay, this is all About our front end and next we will talk about our security for identity federation so So We have to first we have to prevent some risks and then Forex if the then for the for links, of course So I will lead I will list some what we have done, but not all of this just for security, of course just Some what we have done also about Samo assertion harmony I have mentioned that of course way the summer assertion almost Just validate once if the if the same assertion come to twice Oh and oh more than three times it will be rejected and also with the time step to Check the expiration and we also have the Enterprise and enterprise level security management, which means we have Permissions and access security From different use groups and users Also, and Of course, we have a cloud service called the cloud chase cloud chase this service will Record all the will record all the information which Such as federated the user log in log out and Any actions they have done to our cloud services. So Anything that the federated users It down will be recorded at this service. So the administrator Can check also audit Actions so federated users have to have done Okay Okay, then next I will show you a live demo for Federated other do it. I'm sorry The German German research network, okay, perfect Federated with open telecom cloud Dfm Okay Okay, I'm I'm prepared something So we seem to be not as lucky with the demo gods as the keynotes have been but that had that had to happen sometime Okay, okay, it's still not on the screen. Oh Yeah, okay, okay. Okay. This is our portal of course open telecom cloud so here we select the projects and of course our services and There are another a lot of services we have provided and Identity and access management service Also, first we create a user group for the identity Federation here we call Here we call the siblings at the main. So this is a project here and we just Have the rights of IMS and I'm the server and the main street so that and then we create Here we have You can see we have went one tenant for 10 identity providers so D4 for the Dfm we have created here and We can see This is a login link for the Dfm and The metadata file and also This is Yeah, edit This is a mapping rules. We can see we here. We use a wild card here and the match to our local group Sheblist show list and the main and the user of course use the user ID and At Dfm so So I'm sure if we use this login link try to Direct, okay here, okay, it will Delay delact to the Dfm portal here. This is a German research network. So here we can Import our username of course just a test Okay, and username Well password sort of okay success. I then you can see that The user from the Dfm have logged in here. Oh This is a long ID very long so This is the name the federated username and I think I have sure that This is ID and at Dfm. So We have gave the right to the project here at your D. I think we're running out of time. So Maybe we have just One or two minutes for questions. So if you have a question, please step up to the microphone So that it's also on the recording You said that you had to add additional Verification of the SAML assertion Beyond what's currently in Keystone? Why was that necessary and what are you additionally validating? So So you means that our summer so what do we have done to the summer assertion? We So we use So we do not use as we have shown we do not use the ship list or melon for the same assertion so we have right a Model so that we can Do everything we can so sorry So we have a right a model so that we can process Several assertions as we wish so So we can We can decide how the thermos assertion will be accepted just for once or twice or and then so on I'm afraid. I'm not sure if it's Nice work. The question I have is you did some extension enhancements to Keystone. Did you Feed them back into the community Keystone version so that the broader community can actually look at this and benefit from your from your great work Currently we have not okay puts the put the Keystone Keystone patch to the community because It is We have first of all we have a lot we have more works to do for the patch and also This is our Difference from the community version. This is our Community version is for this is our Advantage special advantage, of course for open telecom cloud My name is Rodrigo Hi, it's on core and one of the stuff that I work at upstream is Federation and I Have a doubt why you would need multiple IDP spare domain and When you act as a public cloud provider one possible use case might be a reseller one where you just Resell part of your capacity to a sub provider that then again needs to have Maybe multiple IDPs in that single domain that he is responsible for Okay, so this is probably something that that is that is really special for a foreign open stack based public cloud okay, so You are welcome to give it back to the community. I'll be really interested in in talk to you and maybe raise your use cases to the team so Okay This is actually interesting because you are not the first person that complains about this one-on-one Mapping between IDPs and domains. So I'll bring this up. Thank you. Yeah, okay Great. So if there are no further questions, then thanks for having us enjoy the rest of the summit Have a nice day. Okay. Thank you


So recently I decided to begin testing the most popular YouTube trading strategies. During my research I came across a bunch of channels that post up different strategies that claim to have 60, 70 or even higher win percentage making insane profits. But what I found is that most of these strategies didn't actually work. So what I'm doing for this video series is picking out the most popular trading strategies on YouTube and then coding together a bot so that I can back test these strategies using TradingView's back testing feature. I then show you guys the real results and win rates of these strategies with over 2,000 back test trades. Since I will have these strategies coded into an indicator, I will take the best performing ones and create some trading bots that I can test these strategies with actual real money. This is definitely going to be a fun experiment and who knows we might actually find some good strategies. So without further delay let's dive right into today's video. What's up guys I'm Jay and welcome to Bitcoin Daily. Remember that this content is for educational purposes only and is not financial advice. Always do your own research before risking any of your own money. So if you're new here and you enjoy this video don't forget to subscribe to the channel and smash that like button. Let's dive right in. So on today's video we are reviewing this strategy here from TradeIQ that claims you can turn $100 into $5,000. This currently has over 155,000 views and the title is this insane scalping crypto strategy will make you filthy rich. In the video he shows that this strategy has a win rate of 60%. After taking a total of 100 trades and he made a profit of 391.25% on just 100 trades using this strategy. He did his test on the five minute chart so today we'll be back testing this. Not only the five minute chart we're also going to look at the one minute chart, 15 minute chart, 30 minute chart, one hour, two hour and four hour charts. We'll do all of this by coding together a bot with the exact entry and exit rules so that then we can back test this as close to perfect as possible and get some real results. So let's go ahead and jump right into the strategy. The first thing you need to do on your chart is switch it from candles to Haiken Ashi. So if you guys remember from our last video we told you guys that any video that does a back testing strategy using the Haiken Ashi candles, the strategy probably doesn't work. If you look at this photo here you can see that these are normal candlesticks and these are Haiken Ashi candlesticks. You can see that there's a lot more green on the Haiken Ashi versus against regular candlesticks. If you look at it again here on the move up, this is basically all green over here. Look at this big red candle that does not exist on the Haiken Ashi chart. The reason for this is because the Haiken Ashi candles don't give you the actual real-time prices. What it gives you is an average price of the previous candles. So the closing price on a Haiken Ashi candle is the open plus high plus low plus close divided by four and the open price on a Haiken Ashi candle is the open of the previous bar plus close of previous bar divided by two. So if we split our chart into two with the left side being Haiken Ashi, right side being normal candlesticks. If we look at the last closed candle, you'll see that it opened at $20,389. If we look at it on the Japanese candlesticks, you'll see that it opened at $20,404. So about a $15 difference already on the open. Let's look at the close. This closed at $20,398. This closed at $20,405. That's a $7 difference. You might say, well $7, $15 is not a huge difference, right? But if you do this over and over and over, over 100 times, it begins to add up and it vastly affects your results. We showed you guys on our previous video what that looked like. When we ran all of our back tests on the Haiken Ashi chart, everything was literally green and profitable. When we ran the same exact strategy over the same exact amount of trades, using the same exact signals except opening them and closing them using real-time market data, which is candlesticks. This is what it looked like. And as you guys can see, it is a huge, huge difference. So now that you understand the difference between Haiken Ashi and Japanese candlesticks and why back testing on Haiken Ashi chart is inaccurate, we can move forward to the indicators for this strategy. So for our first indicator, we're going to use the exponential moving average. If you just search EMA, click on moving average exponential and this will add it to the chart. All you have to do is double click it and then we're going to change the length of the EMA from 9 to 200. We're going to go to style, make it a little bit thicker just so that we can see the line a little bit better and hit okay. Our second indicator is going to be RSI, the relative strength index indicator. If you just type in RSI, you'll see it right here relative strength index. So we're going to leave the inputs alone here. We're not touching those. What we're going to do is go over to style. We're leaving the RSI and the RSI middle band and we're basically taking everything else off. So I'm going to take all of these off, leaving RSI middle band taking these off. I'm going to change the RSI middle band from these dots to a line and then make it a little bit more visible. So it's a little bit more obvious and hit okay. The third and final indicator that we will need for the strategy is going to be the parabolic SAR by Evergett. Just click on that and now we are set with all the indicators that we need for the strategy. I'm going to open up the SAR. I'm going to leave the inputs as is, go over to style, take off long start, short start and trade state filling. Put the cell labels above bar and the buy labels below bar. Then we're going to hit okay. So let's go over the rules of entries for the strategy. In order to enter a long trade, there are three things that need to be happening. First, we need the parabolic SAR to be giving us a buy signal or for the dots to be green underneath the price. The second thing that we need is the price has to close above the 200 day EMA. And the final thing needed is for the RSI to be above this line, which is the 50 level. So when those three things happen at once, that is a entry trigger. So if we were looking for a long entry, you see the price right here is above the 200 day EMA. I am getting a buy signal here from the parabolic SAR and the RSI is above the 50 line. So my entry would have been here on that close. I'd be looking to set my stop loss below the swing low. So similar to the last strategy, in order to take profits, we're going to wait until we get the parabolic SAR to switch over to the top and give us a cell signal. So in this instance, we will be closing our trade on this candle right here. So if we closed on the close of that candle, it would have closed right about there. This would have gave us a move up of 0.57% in a risk to reward ratio of 0.73. So now we're doing the opposite. We're looking for a cell signal with the dots on top of the price. We're looking for the price to close below the 200 day moving average. And we're looking at the RSI to be below the 50 mark. So here we got a cell signal, but the price was still above the 200 day. So we wouldn't trigger that entry until this candle right here that you can see closes just below the 200 day. The RSI is below the 50. That would be where we would open our trade our short position. Once again, we're setting up our stop loss above the swing high. And then we're taking profits once the SAR indicator flips into a buy signal. So that would have been right around this close right here. So this trade would have made a profit of 1.43% with a risk to reward ratio of 2.42. So now that we know our entry and exit rolls, the next thing we need to do is get our bot coded together to match these exact rolls. Alright, so we've put our bot together. Let's compare its entries and exits to the examples that I gave you guys. So like that, we can confirm that it's following our exact rules. So here we saw this entry right here. Our bot entered it basically at the same exact spot. It actually entered on the open of the very next candle. You can see that it set its stop loss below the swing low, basically the same area that we're in. And it took profits pretty much the same exact spot where we took profits. You could also see that it took some extra trades here where we got buy signals price was above the EMA and RSI was above the 50 line. Exit it here on this sell signal entered again here and sold again there. It wasn't until here where actually opened a short entry. So you can see here right on this candle, all our rules are met. It set up the stop loss basically in the same area where we set up our stop loss and it closed its short position in the same spot where we closed our short position. So now we've compared our bots entries and exits with our manual entries and exits to make sure that they're the same and that the bot is following the exact rules. So in the video where they showed the strategy, they did 100 total trades that a 60% win rate and a PNL of 391.25%. So we're going to do our first back test on 100 trades on the five minute chart so that we can see how close to these results we might be. All right, so we just did the back test on 100 trades and here's our result net profit came in at 57.68% with a win rate of 53%. So our win rate is very close to this one. His was at 60. We're at 53. Depending on how the market was acting throughout that period of the 100 trades could easily change this. So we're not too far off on this. However, on the PNL, that's where we are very far off. Of course, again, if he hit a few big, big trades that could potentially be the difference. So not bad, right? Wrong. Let me explain. This back test was done again using the Heiken Ashi candles. When you use the Heiken Ashi chart, these entries and exits are not accurate because they're an average of the average open and close of previous candles. So because of that, you can't accurately back test trading strategies using the Heiken Ashi chart. But what you can do is use the Heiken Ashi chart for the strategy to signal and indicate entries and exits, but you must open and close your trades using candlesticks. And that's exactly what we did here and what we're going to show you in our back test today. So if we just flip this strategy over from Heiken Ashi over to candles, you will see a huge difference here on the results. Our net profit is now down instead of up minus 33.77% after 100 closed trades with a win rate of only 42%. So now when we compare it to this video after 100 trades, we are way, way off of these numbers. So again, 100 trades is really not enough data to really know how a strategy is performing. So let's go from 100 trades to 300 trades and see what that difference looks like. So you can see after back testing it for 300 total closed trades, our net profit is now down 52.45%. But our win rate did go up to 49.33%. So to show you guys the difference between opening up these trades on candlesticks versus Heiken Ashi, we back tested 300 total closed trades on the Heiken Ashi chart. And you can see the big difference in profit. Our profits now 867.29% with a percent profitable of 58.67%. So that's when we start to realize that now these numbers look a lot more similar to these results that they show on this video here. This is why I keep trying to emphasize to you guys the difference between a strategy on the Heiken Ashi chart versus on actual candlestick chart because you can get some insane inaccurate results and numbers exactly like these right here that are just inaccurate. You will never get these numbers in the real world. So now I'm going to back test this on seven different time frames and do 2100 trades. I will be using the Heiken Ashi chart to give me the entry and exit signals, but using the candlesticks chart to actually open and close the trades. We'll see if maybe this strategy works better on different time frames or if it's just not a viable strategy. Alright, so I have now back tested this strategy 2100 times with the Heiken Ashi chart and 2100 times with the regular Japanese candlesticks. I want you guys to be able to see the results from both sides so you can see how inaccurate the Heiken Ashi can actually be. So first off, we're looking at the results for the for Heiken Ashi. You can see that everything, everything, everything is green. Everything is profitable. On the four hour after 300 trades, we're talking about 5888% net profit on that.  Now when we look at the same strategy except opening and closing with Japanese candlesticks, now this tells a different story. Very interesting that the one minute, five minute and 15 minute are all red through 100 trades, 200 trades and 300 trades. The 30 minute through 100 and 200 trades is also red. Once we got to 300 trades, it began to hit the green. And then from then on, basically everything was green, the one hour, two hour and four hour time frames were all green. Now I couldn't back test 300 trades on the four hour because it just went too far back and my trading view didn't go that far back. But when we went back a few years, 1,186 days, even though we did get a positive net profit, you would have actually had more money if you just bought and held Bitcoin at that point in time versus doing the strategy. Everything else was pretty much in profit, not only net profit, but if you held it against Bitcoin at this specific time right now, it would have outperformed Bitcoin. There were a few of them where it had circumstances where Bitcoin was outperforming it during its all time highs. And then once prices fell down to the current levels, now the strategy is outperforming Bitcoin.  But as you guys can see on the bigger time frames, one hour, two hour, four hour, the strategies is not too bad. I would probably stay away from four hours. And if I wanted to put some real money onto this, I would look into the one hour and two hour kind of compare them together and see what I think is the best bang for my buck. Just looking at it from a profit factor standpoint, it does look like the one hour could be the sweet spot. If you look at this one right here, 242 days, this one's 265. This is as close as we can get to each other. You'll see that the one hour was outperforming and that's because of course the one hour is taking more trades than the two hour time frame. So if I was looking to do this strategy and implement it, I would probably be doing it on the one hour chart. As you guys can see, it is profitable there. Here's the results for the one hour time frame year to date. If we just did this exact strategy from the beginning of the year, we would be up 46.93% year to date, 255 closed trades, a win rate of 60%, profit factor of 1.197. Let me know what you guys think about the strategy and if there's any optimizations that you guys would make to it to make it better. In the comments, drop any other strategies that you would like for me to review. So I think we're kind of one for two. I would call this one somewhat of a success versus the previous one that we tested, but I'm definitely excited to continue testing more and more of these strategies to see what's the best strategy that we can actually find. If you enjoyed this video and wish to see more reviews on these strategies, make sure to smash that like button and subscribe to the channel, turn on notifications so that you don't miss the next one. All that being said, if you guys want access to the codes for these indicators, for these strategies, so that you can set it up on your own trading view or maybe even on your own box, you guys can gain access to all these codes by gaining my VIP Discord. In my Discord, I will be sharing all the coding for all the scripts, all the strategies that I review every single week. I will also be sharing the exact trades that I'm personally taking myself in real time every single day with entries and exits. If you guys are interested, go down to the description where I have a link to my mentorship group. Also, make sure to check out this video that we just did last week where we tested a trading strategy on trading view that was claimed to have an 80% accuracy. I think you guys will be shocked at the results. Click the video on the screen right now. I'll see you guys on the next one. As always, peace and love.


Good morning. I'm sure we'll have some more people kind of trickling in but I thought we'd go ahead and introduce our speakers today and get started. Our first speaker today is Barbara Morosco. She's a clinical associate professor here at the Moran. She's going to be speaking to us about research opportunities here. It should be very interesting that we also have from the lower campus Joyce Mitchell. Oh here in the medical school. Thank you. Joyce Mitchell. She's the associate vice president for academic health information technology professor and chair of the department of biomedical informatics. She's going to be speaking to us about a clinical cohort finding system to help us with our research as well. So please welcome them. So I actually have Steve to thank for this opportunity and sort of the stimulus here to think about doing this. So when I sat I don't know if Mark's here. Yes. So when I was here Mark Grave Grand Rounds maybe about a month ago primarily focused on the residency program and hit upon a few topics on what he had heard from the residents in terms of research that was available here at the Moran. When I was joining or coming on board and talking to Randy we started talking maybe about six years ago. It was the first time I met Randy. I saw the opportunities here and I said wow this is just such a great place to do all aspects of research. I don't have a PhD. I've never really been in a lab per se working at the bench except now with Bala doing some animal studies. But there's so many types of research and it's really here. It's right here and Steve also opened up another whole opportunity opportunity that's here through further which is what Dr. Joyce Mitchell is going to speak about. So this is supposed to be interactive. It's supposed to be creative. It's really geared towards the residents medical students fellows. So what is research. Well it's a careful or diligent search. Studious inquiry or an examination especially an investigation or an experimentation aimed at a discovery and interpretations of facts. Revisions of accepted theories of laws in the light of new facts or practical application. It's the collection of information about a particular subject. So basically just ask a question any question. There's all different types of research observational research correlation research quasi experiments and true experiments. So what's observational. Well case studies human behavior studies primary characteristic is that the phenomenon are being observed and recorded. So you can even do a prospective observational study in triage. How many patients come in with corneal ulcers. And what's the inciting event. Is there a difference in patients presenting in the summer versus the winter. What about dry eye. Dry eye is supposed to be seasonal. In fact I was just at a conference this past weekend where I don't know how many of you are familiar with eye gait. So it's I ontoporesis for the treatment of dry eye. And they ran a clinical trial phase three. No surprise did not meet their primary endpoint. But what they did find was that the recruitment of the sites differed over the year. And the results for that site differed by season. Very observational. Informative correlation. This is a very busy slide. But basically it examines the co variation of two or more variables. So let's think about this. So research on cigarette smoking and you want to see if there's a correlation between lung cancer and cigarette smoking. There's two variables here. The variables the smoking and the lung disease. Do they vary together. Do they vary at the same rate.  Correlation research can be accompanied by various techniques. You can do it retrospective. You can do it prospective. You can do a database analysis. You could do a cross sectional study. Just bring some patients in. Again I'm going to use triage. So patients come in with corneal ulcers. What's the correlation between the corneal ulcer and contact lens use. Over the past five years. What's the correlation between contact lens use and keeping in their contacts and corneal ulcers. Again correlation. It's observational. Nothing is manipulated. You're not treating. It's not interventional. And it's not necessarily casual research. Correlation research is often conducted as an exploratory or a beginning research. And again with Dr. Joyce Mitchell here when she talks about what can be gained from this further database that everyone has access to. It's really exploring correlations. Steve and I were talking about there's a lot of research now on sleep apnea and glaucoma. Do the glaucoma patients here at the university have a higher correlation with sleep apnea. The data is all over the place. Some people have found yes there's a correlation. Other people have not searched the database. See. Look at the diagnosis. Quasi experiments. I actually like this term. So they're similar to true experiments. But they use naturally formed or preexisting groups. So the subjects can't be randomized. And it's not a true experiment but it's not a junk experiment. An example would be lung capacity in old and young individuals. So there's a lot of confounding variables. You've got pollutants. You've got cigarette smoke. You've got demographics. You've got age. You've got where the patient lives. So there's a lot of differences between the groups that you can't control for. But again some of those differences could account for your findings. So you design you carefully assess the casual or causality with your quasi-experimental designs. And again in some ways it's similar to a correlation study. But you can control one of the variables. So maybe you can have the patient stop smoking. So in some ways it's partly interventional but you're not controlling as you would for a prospective clinical study. And this is the true experiment. So this is probably what most of you are familiar with. You have at least two groups. You have an experimental group and a control group. And each group will receive a level or change of the independent variable. So you've got an independent variable. You've got a dependent variable. And the dependent variable will be measured to determine if the independent variable has an effect. So let's put this into perspective. Glaucoma study. Your dependent variable is your IOP. You're going to see if your independent variable which is your glaucoma treatment is having an effect on your dependent variable. And then you're going to ask if there's a correlation with that IOP and progression over long term. So there's a correlation component. The control group is going to provide us with a baseline. And in true prospective randomized studies and I'll get into a little bit about that. You do have a control group because you want to know what is happening if you're not intervening with that independent variable. All subjects should be randomly assigned and be tested in parallel. Because again, as we saw with my example with the IGATE, patients were not necessarily treated in parallel. You had one site enrolling in June. The next site enrolling in December. So they were treated within the site in parallel. But they were actually treated at different time courses. And that actually affected the outcome in this dry eye study. And again, it was pretty a pretty major deal because they failed to meet the primary endpoint in a phase 3 study. Should it be conducted as a blinded or masked study? And it's funny. You can always tell the people that I joke about this. You may have heard me say this, but you can always tell the people who have worked in ophthalmology because we never say a blinded study. We always say it's masked. So what are the components to a controlled prospective study? Experimental or the treatment group where you vary that independent variable. You have your control group. You have an independent variable as I mentioned, dependent. It's a random assignment. And again, it could be double blinded or masked. Investigate or a single masked is another term. Various forms. You can have a clinical prospective study, which is interventional again, phase 1 through phase 4. And again, you can have non-interventional, and we spoke a little bit about retrospective case studies, database analysis, we'll go more into, and literature reviews. There's various levels of evidence. And when you think about the level of evidence, the tip of our pyramid is systematic reviews, which are reviews of what's already in the literature on published studies. So for instance, if you did a systematic review of all the Lucentus studies and came out with a conclusion on the efficacy and the AEs, that would be probably the highest level of evidence, because it's a conglomerate of studies. Below that again is your randomized controlled trial, going down cohort studies, case control, case series. And then at the bottom are editorial and expert opinions, which still carry weight, but their level is on the lower end. So what's an interventional clinical study? We call them randomized controlled trials, RCTs. And again, they're randomized, and that is the preferred way to assign participants to control or interventional. This eliminates and controls for variables. So you want each treatment group at the baseline, that patient will look very similar across treatment groups, age, race, demographics, baseline dry eye, corneal findings, IOP, et cetera. And then again you want to mask. So you want to remove the bias. You don't want to know that Mrs. Jones is actually getting treatment. You want to know or placebo. You want to know that you don't know what she's receiving. And again, it removes the bias, both of her and you. An assignment of a participant is determined by a formal process of randomization. I've been throwing around randomization, but it's really just a random numbering. And you can, this can be accomplished in large clinical trials, either through a IVRS or an IWRS, or even in the clinic if you have a small trial, you can just basically say, okay, patient one, group X. Patient two, group Y. Patient three, group X. And just assign them randomly. So whoever walks in the door. Chances are based on statistics and probability that if you have a large enough group of patients, they will fall fairly evenly across the treatment groups. And that's what you hope for. So why is randomization so important? Well, it's the preferred way of assigning participants, as I said, to control an intervention and it eliminates and controls for the variables. It also establishes similar patients across treatment arms. To test additional variables, you can stratify. So again, let me, I'll get back to a Glaucoma study. So I want to know if my treatment X works better than a placebo or a vehicle. But I don't know if it's going to work better if patients have IOPs from 21 to 25 or from 25 to 28. So I can stratify so I can have within my first treatment group, two groups of patients. The lower IOP and the higher IOP. And they'll both receive treatment X. My placebo, higher IOP, lower IOP. So within that treatment arm, you now have two groups and you're also asking the question, does the treatment work? But does it work differently between those two IOP levels? What's the placebo effect? And I was thinking of when Tony Adamus was here and was talking about the patients who were able to see better. And I think this happens all the time. You know, the patient thinks that they're getting better or they think there's something going on and they try a little bit harder or they're reading a little bit better. But placebo, when I looked into this, actually I was quite surprised because there really is some conscious belief in the patient that the drug is working. Or at least if they're getting the intervention. And there's a subconscious association between recovery and the experience of being treated. And we see this all the time. Again, even in glaucoma studies, the patients who receive placebo across the board have a two drop in a two millimeter drop in IOP. So when you look to see if your intervention, very early glaucoma studies, if you're studying your drug against your vehicle, just assume that your placebo, your vehicle group, no active, will have two millimeters of mercury drop. And this has been well reported, well studied. So again, if you're looking for a benefit of your drop, you have to almost look at four to six because your placebo will have some effect. And researchers, again, have demonstrated that it actually may be a response from the brainstem. So there is some subconscious and conscious components to placebo. So again, very important to mask. So how do you control the placebo effect? Well again, patients do do better in clinical trials than they would just coming into your clinic. If they are receiving a placebo in a controlled trial, maybe they're more responsive, maybe they're more attentive, maybe they're following directions better in these clinical trials. Maybe we've also weeded out the non-compliant patient, which is another reason why patients always do better in clinical trials. And I sort of mentioned this already. So basically when you're thinking about clinical trials, recognize that there's going to be a placebo effect, accept it, and then just plan for it in your statistical analysis. So just to briefly go over some different phases of clinical trials. So a phase one is generally a dose-ranging study in healthy individuals, and you're really looking for safety. Generally open label, although it could be masked, and you can measure formical kinetics of the drug. So you're looking to see if your drug is actually getting absorbed, what the exposure is, and if there's any safety concerns. Phase two, I like to think about that now you've taken that drug and you said, okay, it's safe in healthy individuals, let's put it into a diseased patient population. Because you never know if the safety will be different in that patient with the disease. And again, I think about our ophthalmology patients, a drug that's really irritating to the cornea that you're going to use for a keratitis patient may be well tolerated in a healthy white, quiet eye, but actually could be very irritating and very intolerant in a patient that has an ocular keratitis. Generally primary endpoint is safety, although you do want to see an efficacy signal. So you'd like to see that your drug is having some effect and is doing somewhat of what it's supposed to in that disease population. Phase two B's are generally larger, and these help you to inform the phase three, which are the largest studies, which are generally the regulatory studies. So your phase two B is statistically powered for an efficacy single, and again you want to inform your phase three. So here's where you're going to know how large is your effect. What are you going to need to do to power your study to actually get a signal, a statistically significant signal. And then also what's your comparator. And your phase two B will actually help you determine that. And again, your phase three, obviously everybody I think for the most part is aware in just very, very large studies. We tend to be small in ophthalmology compared to cardiovascular. Some of those studies are thousands of patients, three, four thousands patients, thousands of patients. There are also millions of dollars, and we tend to be several hundred patients. Again, phase three, you want it to be more representative of real world. Sometimes the criteria are a little bit relaxed. They may not be as stringent in terms of the patient that you're studying. And chronic conditions can have very, very long phase three studies. Even if the primary endpoint is only a three month or six month, a lot of times these patients are followed for years out work, because the FDA really wants to see if you're treating chronically what's the safety over time. And then phase four, these also tend to be long studies. They're open label. They can be epidemiologic. They can be observational. They also can be massed studies. It could be extensions. But it's really, again, to capture real world experience. So take the patient out of the clinical study, remove the placebo, remove the, you know, the clinical parameters of being stringent and the compliant patients and really see what the real world experience is with the drug. And we've seen this with BIOX, BIOX had a safety signal, had a black box. Other drugs actually have been pulled from the market. And, again, it's really to capture what is that experience beyond that clinical trial population. So what are the research opportunities here at the Moran? Well, they're tremendous. And they're traditional clinical trials. And we've got, we're fortunate enough to have Dr. Bernstein here leading the clinical research, as well as Deborah Haverson, who manages the clinical trial. So, again, they're definitely the go-to people if you want to hear or learn more. You can do investigator-initiated research. So IIRs, you can actually apply to a pharma company. And you can use a compound that's in development or is already approved. And you can look at novel new treatments, or you could just do an additional study in the same group of patients. So I'm trying to think what comes to mind. Think about, I don't know, erythromycin. I'm starting to think of everything that I was talking about today. So you want to look at erythromycin. I don't even know if it's approved for angular blepharitis. I don't know. I don't think it is. Okay. Divitis. So it's a perfect example. So angular blepharitis. How many times do we use angular blepharitis to treat, or actually erythromycin to treat angular blepharitis? You could do a study looking at the use of erythromycin in treating angular blepharitis versus maxotrol, gentamycin, exactly. If you do go to a pharma company and want to use a drug off-label. So, for instance, if you want to use Lucentus for the treatment of post-tribeculectomy fibrosis studies. A lot of times, if they're going to allow you to do the study and or give you grant money to do the study, it has to make financial or commercial sense for them. So it has to be an area that they would be interested in looking at or pursuing, perhaps. Then it makes much more economical business sense to them. But it actually is a very neat way to do research with drugs that you have at your hands. So it doesn't need to be an experimental drug, it can be something that's actually in the clinic. So retrospective chart reviews. Again, just ask a question. And this came up recently with a patient that I had who was on Durzal. And she had a very, very pronounced IOP spike that was very, very difficult to treat. I don't know if we really know. We know that Durzal will cause an IOP spike, and we've got cataract surgeons using it routinely, post-operatively. But how rapid is the spike? What's the degree of that IOP spike? Is it more difficult to treat? What's the onset? Is it at four weeks? Is it at six weeks post-operative treatment? There's so much here that we don't know about this drug. And again, this is a drug that you have at your fingertips. It's just been approved. It's just been marketed. And it's a very, very strong steroid. It's worth studying. Look through your charts. If this is a drug that you use routinely, follow your patients. Just ask some questions about it. Or again, the medical students, the residents, ask some questions about it. What don't we know about this drug? We don't know a lot. We know very little. And again, retrospective chart review is a great way to look and say what's happening or what had happened to these patients. And you can always use historic data, too. That's another neat thing. There's a lot of historic data on the rate of IOP elevation in steroid use with dexamethasone, with prednisolone. So you've got a historic database that you can compare it to. What's the most common ocular pathology at the triage? Again, I wonder about the patients that, guys, see a lot of corneal ulcers there. And there's a lot of patients sleeping in their contact lenses. Are there more younger patients sleeping in their contact lenses? Is that why they're having more corneal ulcers that present? And is there a greater incidence of corneal ulcers here at the Moran than, say, in another large urban city? Literature review. There's been a lot of recent interest in, again, I'm just going to throw out some ideas, caroidal thickening in AMD and also in glaucoma patients. And what is the day to tell us? It's sort of all over the place. We know that if you measure caroidal thickness, you're getting a measure of caroidal blood volume and ocular blood flow. Well, is there a correlation between AMD? Is there a correlation between glaucoma? You could review all the present literature and do a literature review, publish an editorial, publish a review of the literature. So I wanted to pull up one example. David DeMille over the summer had come to me and said he was curious as to what patients looked like when they entered a glaucoma clinical trial and did various inclusion or exclusion criteria affect the outcome? So again, thinking about that IGATE example, patients were enrolled. Oh, another interesting finding that they found was that during the study patients that had decreased corneal sensitivity actually makes sense, had worse outcomes in the fact that they did not notice as much of an improvement. Now, they did not stratify or they did not set inclusion criteria based around corneal sensitivity, but this was something they found. So obviously, if you're conducting a dry eye study and you want to know if patients feel better, you have to enroll patients who can actually feel their corneas. And this is what they learned retrospectively. So David had said, you know, well what about when you enroll glaucoma patients? You're talking about IOP, you're talking about demographics, you're talking about baseline IOP, you're talking about prior medications, diagnoses. So he was really instrumental and just did a very thorough literature search on the phase two and the phase three studies. He had some criteria by what he used to define the studies he looked at. And we ended up with four papers. So three of which have been accepted already. And it was pretty cool. You know, it really was just a question. It was just a question. Database analysis, and this is where here I'm going to introduce perfect timing to Dr. Joyce Mitchell. So again, Steve was working in triage with me one day and he said, did you know that there's access to this database that really just has a wealth of information? And we can actually ask questions. We could say what's the correlation between glaucoma and sleep apnea? We could ask the question between AMD and diabetes in the Utah patient population. So that was pretty much my introduction. And Steve has been instrumental in again introducing this to me. And I thought it was so valuable that I wanted to introduce it to you. So I thank Joyce very much for being here. I'm going to let her introduce herself. But with that, Joyce Mitchell. Thank you.


Thank you very much, and let me immediately tell you that In my talk, I would really would like to consider signboard on type models more precisely the FRG study of signboard on type models which seems to be a little orthogonal to the issue or topic of the Today afternoon I'm considering Higgs physics or whatever But I hope that I'm able to convince you that this is not the case So that's why I put these two words conformal field theory and Higgs physics Because what I would like to say what I would like to present you some application of signboard on type models models towards these Directions and let's see what we can see So why signboard on models first of all the definition a very brief definition of a signboard on model It contains the periodic self-interaction Phi is a real single component Scalar field so the simplest case whatever one can imagine the model contains two parameter the fury amplitude and beta And I put three issues here and these three issues is a kind of Commercial stuff. I would like to in the beginning of the talk show you that that the topic so this signboard on stuff can somehow related to the Some some possible talks of today. For example, let me just jump to the second one Higgs physics We have talks on Higgs physics in the afternoon. What do I mean relation of signboard on models to Higgs fixies? I will tell you BKT, this is the first one. I put it in because I consider it as probably the most important one This is the playground for signboard on model BKT means Berezynski, Kostelis, Thales phase transitions or topological phase transition and indeed signboard on type models can be used to attack BKT type phase transition and Pavel Jakubczyk will present at least for me a very exciting talk I hope so on the amplitude fluctuation O2 model xy model whatever and this signboard on representation Brings us a tool to attack the problem in a different way and there is this first issue Which is conformal field theory and more precisely? Zomologic of C function and C theorem. This is basically the the main Ingredients of my talk. So I put it in a kind of reverse order So the most I would like to speak about C function stuff a little Little introduction what I mean signboard on physics to vart Higgs potential and just mention a few words about BKT Of course limited time. I cannot really Put all the words what I had in my mind So if I wish to do this scenario go through this scenario Then certainly I need a method and the method is not surprisingly FRG Very very briefly in a nutshell So we know that the veterinary equation has a form which is the simplest in that case because we considering a simple single component scalar field theory You know the story are is the regulator function We also know that the regulator function should fulfill some requirements otherwise free to choose So this brings us some difficulties if we consider the exact FRG equation and solve it then the regulator dependence is not an issue But we we has to make truncations. So we know that the truncated flow depends on the regulator and we really need Approximation so I picked up to generally use approximation the first line is the so-called gradient or derivative expansion where the gamma the running gamma is Expanded in terms of the derivative of the fields. That's what I use very frequently and Leading order term Z the way function organization set to be zero That's the leading order, which is called local potential approximation So we will have results in LPA and also LPA prime. I will tell you the details further Approximation one can use for example a tailored expansion of the potential or the wave function organization And if we cut it then it's certain in approximation So our results and my results what I present today will depend on and cut will depend on How far I go to the derivative expansion? Okay, that's the general warning for you Now comes the sign Gordon stuff. This is the main issue. So let me first really go through how Different extension of the sign Gordon model can possibly be written. So This is as I told you a single component scalar field theory now. I defined the equal to Dimension I mean Euclidean dimension and indeed the model has two parameters you and beta And the model has two symmetries that to and periodicity reminds you that periodicity is a discrete symmetry So even in D equal to the model could have a non-trivial phase structure and indeed it has it undergoes the so-called topological or Btk phase transition, which is characterized with this critical value of the frequency beta square equivalent by There are some kind of issues where the sign Gordon model has been used mostly in statistical physics. I don't want to iterate it The next step the next idea to generalize this sign Gordon is just to add Explicit mass you may ask for what these are the reasons this model has been used again in super fluidity Superconductivity, etc But the idea what I would like to show you that probably this massive sign Gordon model can play some role in Higgs physics I will tell you what I mean, but it is clear if I add a master here Then it immediately breaks periodicity. So periodicity is gone and what remains is a Z2 symmetry So one expect a kind of easing like phase transition. That's one thing Another thing one can play with coupling of many sign Gordon's then you have a coupled system We can also use it for superconductors. I mean to describe vortex behavior, but at this point. I don't want to Tell you more about this kind of extension Instead I would like to play with the frequency beta now. That's the main issue of today Let me again record the usual sign Gordon and do the following trick in order to obtain the so-called cinch Gordon one has to do the following replace the real valued beta With an imaginary one so I beta then the cost becomes a cost and remind this is not a periodic function So one expect a Taylor expansion. I mean one expect that the Taylor expansion is a doable approximation for that model Go ahead. Then what we have is a kind of easing type fight to the 2n model We know that the fight to the 2n model has two phases even in the equal to now the question If you look up in a textbook, you will find that the cinch has a single phase. Why? Maybe the answer is clear for everyone, but I would like to tell you if you don't know What would be the solution of this kind of ambiguity or puzzle? Okay, so we would like to attack the problem by FIG and see what is then the phase structure of the cinch again and a kind of Generalization which is the so-called shine This is really the last one. I promise you the shine contains instead of an imaginary beta a complex one But please observe in order to be physically reliable Theory one have to take the real value which brings you a cost time a course and if beta one is zero then it is Cosh so a cinch and if beta two is zero then you come back to the sign golden So the shine somehow interpolates between the sign golden and the shine We will also consider the phase structure the C function of this model So I talk about C function. Let's be precise what I mean C function and Let's jump to the word of Conform of field theory or more precisely global and the local dilatation These are somehow related to each other and play a press special role in the equal to dimension Let me let it go step by step. So global dilaton symmetry means that changing let's say the lattice space by a Multiplicative factor lambda which do not it does not depend on the X. I'm in the spacetime If you go if you consider local dilatation, then of course lambda is X dependent Staying in the level of global symmetry one can immediately realize that this is nothing but scaling variance This is the cornerstone of our FRG We know that in the second order phase transition if the model under goes a second order phase transition It is self-similar. So it's scaling variant So one expected that if we really take seriously the FRG and look for the fixed points of FRG And that fixed that points the theories scale invariant. So one finds that this is a nice Situation for global Dilatation symmetry. This is a phase diagram of the sign Gordon showing you to the first time you see two phases The arrows indicate the direction of the flow. This is the separatrix somewhere here So this is one phase. This is the by the way the broken phase And that's the other phase and this is please observe that this is the line of attractive fixed point here They're line of repulsive fixed point and here you find this kind of IR convexity fixed point Okay, these are the fixed points. So one expect global Dilatation symmetry at these fixed points. Now, what happens if I switch to local one? I would like to really jump to be equal to be equal to special in this case The the the theory is not just simply conformal invariant, but the conformal group is infinite dimensional special situation because The conformal and the scaling variance are hand in hand So it means that what is trivially true that if the theory is conformally invariant then it is scary invariant But in the equal to the vice versa is okay. So once it is scale invariant, then it's conformal one So what one expect that the fixed points of the FRG? Also represents a conformally invariant field theory and one can identify The central charge of the corresponding conformal field theory So one expect that these fixed points can be dressed up with central charges and indeed this is true This is what we expect. So for example here a kind of Gaussian like is associated with C equal one the attractive region again We put C equal one and here is this an infrared we put C equals zero I mean we put how? By hand, but that would be really nice to see that FRG work and tell us that the favor that really Computably see that this are the central charges. How can we do it? In order to do it we should really add something as and then comes Zomologic of C theorem which tells us that if we are out of the fixed points We can still some do something we can define the so-called C function Which is a function of the couplings for the sine Gordon. It is the u tilde and the beta square. Okay, so that's a Function which is always a decreasing function from the u-way to the IR and we always take the value of the central charge It at the fixed at once can we construct such a kind of Function in the framework of FIG many papers one can iterate But now I would like to use Alessandro, Julio and Carlos result So taking the formula adopting the formula what they derived in a paper and Try to really use this in order to address such a questions Okay, so the goal is to see how it works for sine Gordon type models now in order to do so one has to make a little further step more precisely the Original sine Gordon contains the beta but in order to go beyond the LPA just for technical reasons It's good to make a kind of rescaling of the field So beta jumps here and becomes the wave function normalization still the model has two parameters Z and u tilde. Okay, that's just a technical trick But I also would like to remind you that this technical trick requires the careful treatment of the regulator So we are using power low type regulator Otherwise we can easily run into a trouble losing the scaling variance, but this is a technical issue So you see I always indicate power low type regulators equal one. So this is the mascot of here are the RG equations But consider this is still an approximation Because I use a single Fourier mode. I adopting the formula which is strictly speaking valid for LPA We discussed this issue with Alessandro Carlos, so you know what I mean So it's just a kind of approximation what we expect that's still viable still doable and let's apply it Okay, so three equations one for the C Function and one for the Z and one for the Fourier amplitude We are in D equal to two dimensions. So the flow equation always looks like this I'd switch to dimension less quantities and here are the results. What are the results? So what we wanted to do is the following Let's consider region one, okay What we want to do is to see that if we start from C equal one And if we go through an RG trajectory, it really runs to C equals zero This is the expected wishful thinking. Let me say and here here you find some results The colors correspond to various values of beta and the green one here is the green one is the best one Why because you see this is start from C equal one and if we decrease K It runs to C equals zero. So delta C is one This is what we expect because for San Gordon, we know that the Corresponding associated central charge is one and this trajectory is lying somewhere here But if we move away from that line and we start for somewhere here It is still produces us some reliable results. Of course under some numerical Uncertainties these are the uncertainties. So at least a 90% or 80% Accuracy we can we were able to reach that's the region one. So up to now This is this could be also considered as a kind of test of Alessandro's Julia and Carlos result and works fluently Now what happens in region two region three? I'm a bit confused telling the truth that we don't know how to associate a C here It's not a fixed point first of all and even if you extrapolate this Playing asymptotic safety or whatever then please observe this corresponds to large beta Large beta corresponds to small Z. So the kinetic term frozen out. What is then the C? Central charge of this theory. I don't know Nevertheless, if he really falls by hand to put C equal one in region three We have reliable results, but as you see numerically, this is not so stable So there is a question mark at this stage and I cannot give you the correct answer I'm open for discussion if you can tell me what you what do you think about what would be the theory in this case I would be very grateful. So that's all what I wanted to say about the same or no Let's switch to singe regarding singe This is a very fast way to show you how effective the effigy for sign or don't type of that Just think the linearized effigy dropping all the nonlinear terms Substitute it just this term take the Fourier expansion of both sides and one can easily reach To read of beta square equal 8 pi. It's so easy. So for sign Gordon the linearized RG works very well Let's try to adopt the same for the singe. Please observe. We have this I beta. So this Plus becomes a minus no beta square Critical value can be determined these signals that no big a taste transition appears in the singe good So what we have? No topological phase transition. This was a kind of trivial reason. Okay, but then what let's go and Blue brutally a kind of fully a Taylor expansion of the model go ahead It's a no it's a non periodic stuff one what one can see immediately that the coefficients are always positive So if you consider this as a fight to the 2n model, we are always in the symmetric phase That's why the model has a single phase. So We are somehow Confirmed that the textbooks are good even FRG tells us that the model has a single phase But let's see how the RG flows works This is what we did in a tricky way and these are the RG trajectories or lines Which really implies that the model has a single phase. So that's about the singe and if I wish to switch to the I wish to switch to the summary of the talk Then I would like to go through this and mention just the various the very last point Which means that what about the shine? What about other interpolating model if you are interested in there is a poster Precisely poster number two and where you can find this shine or whatever But the reason I would like to conserve three minutes for myself to say something about this kind of Hicks idea Now this is the very last thing but I would like to show just three slides, but this is the most questionable part Okay, so I'm very grateful if you can tell me that each time. This is a crazy idea. Forget it or go ahead I like this. So please really do Criticize what we what we plan to do together with my Italian friends. So the idea is the following Took the usual standard back mechanism I I go through this but probably you all know how it looks like take the fix sector Take the usual typical Hicks Lagrange Hicks potential which contains the parabolic and the quadratic term and Perform the steps which requires in order to dress mass for the Z and the W's This is the straightforward thing what we do always Just few things We use a certain parametrization V is of course the vacuum expectation value known from low to low energy experiment This is the Hicks miles measured by the LSE recently So lambda can be calculated using the formula. That's a known thing written in textbooks now What try to play with that and try to introduce other type of Hicks potential. Is it doable first of all? Yes, it is not forbidden. It's not a priori given by the standard model. So one can play with this Can one think about the higher order higher minima? Yes, it is true It's a it's a playground of today because we can play with stability We can play with the ideas in Inflaton dynamics relate the Hicks and the inflaton at the same time. It's a nice thing. I Put two papers here, but of course It is not the total number of papers related to the issues So I'm apologizing if I skip some important thing But I would like to show that it is doable But in every little paper when I when I go through the derivation I always found a kind of polynomial extension of the Hicks Why not try a periodic one seems to be a crazy idea But trust me this drastically changed the phase structure. Why because it has infinitely many minima infinitely many minima so no tailored expansion or no truncation of the tailored expansion It is simply forbidden Why we need this? First of all, let's go through the derivation or what I would like to say that the change Compared to the previous one. It's just this blue one a periodic stuff appear Okay, this is one thing one can fix beta in such a way that the vacuum expectation value of this periodic stuff to be equal to the Normal standard model Hicks potential then remains you you can be changed to fine-tuned to have the same Hicks mass Crazy idea. Am I right and if it becomes more crazy if you just consider a simple sine Gordon in D equal for if you Treat the model by FIG purely the sine Gordon model Be larger than two so in D equal to one finds a single phase now. It's wrong So it's not even doable. It's a single phase. We kind of do it's it's absolutely wrong But now comes the idea if we play with the So-called massive sine Gordon model which contains an explicit master which known to have two phases So it fulfills the requirement of having two phases, but it according to our previous examinations and studies the model Save in a sense that the parabola is always remains positive So we can have a chance to substitute it to the standard model Lagrangian Perform an RG and see whether the stability of this. I don't know how to say extended model remains the same or probably we can somehow escape the unstable Region so in another words, this is a kind of proposal. This is a book which is in progress But before we do any steps, I would be grateful for any comments But that's really the last one what I wanted to say. Thank you for your attention


Hello children, it's story time and today we will read a book about you. What makes all of you so special? So let's start reading. I am me. No one looks the way I do. I have noticed that is true. What do you see here? I see one boy and two girls. I see one boy and two girls. They all have two eyes, two ears, one nose, one mouth, one neck, two hands, little fingers, two legs, and tiny feet. No one walks the way I walk. No one talks the way I talk. No one plays the way I play. This boy loves playing football. What do you like to play? No one says the thing I say. There is no one else I would rather be. I am special. I am me. Yes children, you all are very special and I have a special nursery right for you. I want all of you to sing along and clap your hands. Enjoy. The children, I hope you enjoyed this song. I love this song and I will see you soon with a new story. Until then, happy reading, happy learning. Bye-bye.


This research aims to develop a comprehensive approach to utilizing Office 365's cloud-based services to test student knowledge. It will analyze how these services can be used to monitor student progress, create and adapt testing requirements, and select appropriate tools for use in the educational process. The objective is to optimize the testing process using Microsoft Forms as a tool for assessing student performance. The subject of this research is the usage of cloud services in testing students. The paper discusses the challenges of organizing pedagogical testing, the potential of Microsoft Forms for Assessment, MFA, to address them, and the results of the research which could be implemented in educational institutions that use Office 365. This article was authored by Uv Hritzak and Ov Hritzak.